Loading
Life sciences · Journal article
Diabetology · October 27, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Obesity is accompanied by chronic low-grade inflammation and increases the risk of type 2 diabetes (T2D), metabolic dysfunction-associated steatotic liver disease, cardiovascular disease, and other inflammatory disorders. Growing evidence indicates that metabolic cues generated in obesity actively reshape immune-cell differentiation and function and thereby contribute to disease progression. In this narrative review, we synthesize recent advances in obesity-associated nutrient excess remodel macrophages, dendritic cells, innate lymphoid cells, and T-cell subsets, emphasizing the evidence linking these changes to adipose inflammation and insulin resistance. We highlight lipid-dependent regulation of the T helper 17 (Th17)/regulatory T (Treg) cell balance, including acetyl-CoA carboxylase 1 (ACC1)-dependent de novo fatty acid biosynthesis and regulation of retinoid-related orphan receptor gamma t (RORγt) by 1-oleoyl-lysophosphatidylethanolamine (LPE [1-18:1]), as a representative mechanism by which cellular metabolism controls lineage-defining transcriptional programs. Finally, we discuss emerging therapeutic approaches, including weight loss and glucagon-like peptide-1 (GLP-1)-based therapies, blockade of inflammatory mediators, reprogramming of immune-cell metabolism, and restoration of inflammation resolution. A better understanding of these metabolic–immune interactions may facilitate the development of new strategies for obesity-associated inflammatory and metabolic diseases.